A common feature of B-cell chronic lymphocytic leukemia (CLL) is chromosomal loss of 13q14, containing the miR15a/16-1 locus controlling B-cell proliferation. However, CLL etiology remains unclear. CLL is an adult leukemia with an incidence that increases with advancing age. A unique feature of CLL is biased B-cell antigen receptor (BCR) usage, autoreactivity with polyreactivity and CD5 expression, all suggest a role for the BCR in driving CLL pathogenesis. Among human CLLs, BCRs autoreactive with non-muscle myosin IIA (AMyIIA) are recurrent. Here we identify an unmutated AMyIIA BCR in mouse, with distinctive CDR3 segments capable of promoting leukemogenesis. B cells with this AMyIIA BCR are generated by BCR-dependent signaling during B-1 fetal/neonatal development with CD5 induction, but not in adults. These early-generated AMyIIA B-1 B cells self-renew, increase during aging and can progress to become monoclonal B-cell lymphocytosis, followed by aggressive CLL in aged mice, often with the loss of a chromosomal region containing the miR15a/16-1 locus of varying length, as in human CLL. Thus, the ability to generate this defined autoreactive BCR by B-1 B cells is a key predisposing step in mice, promoting progression to chronic leukemia.
INTRODUCTION
A critical role for the B-cell antigen receptor (BCR) in the development of chronic lymphocytic leukemia (CLL) has been hypothesized, based on the findings of biased immunoglobulin variable (V) region gene usage. 1, 2 Approximately half of CLLs express unmutated BCRs, identifying cases with a more aggressive course compared with those bearing mutated BCRs. 3, 4 These unmutated BCRs in CLL have been shown to be autoreactive and polyreactive, showing crossreactivity to bacteria and/or viruses. 5, 6 One clear example of autoreactivity by CLL is recognition of non-muscle myosin IIA by unmutated BCRs utilizing nearly identical V H 1-69/D3-16/J3 IgH paired with IgKV3-20 IgL 7 found iñ 1% of CLL patients. 8 In addition to binding intracellular nonmuscle myosin IIA, this BCR also binds apoptotic cell determinants, where intracellular/nuclear components, including myosin IIA, are exposed outside the cell membrane as autoantigen-bearing blebs. 7, 9 This suggests that B cells with this BCR provide the initial recognition of apoptotic cells. 9, 10 These findings prompted the proposal that the initial step in CLL may be the generation of autoantigen-experienced B cells 11, 12 bearing polyreactive unmutated BCRs.
In normal mice, generation of CD5 + B cells, termed B1a cells, occurs as the outcome of relatively strong BCR signaling induced by (self)-ligand exposure. [13] [14] [15] Such BCR signal-dependent B1a cell generation is the predominant outcome of B-1 development that occurs in fetal/neonatal B-lineage precursors expressing Lin28b and lacking miR Let-7, as the progeny of fetal hematopoietic stem cells. In contrast, adult bone marrow (BM) B-lineage precursors do not express Lin28b and do express Let-7, resulting in a switch to B-2 development that predominantly yields CD5 -B cells. [16] [17] [18] After birth, the production of B1a cells declines; however, a fraction of B cells generated during fetal/neonatal B-1 development persists as a minor B-cell subset that is maintained by self-renewal throughout life 19, 20 as B-1 B cells. On the basis of their autoreactivity and expression of CD5, B-1-derived B-1 B cells have been suggested to have a propensity for leukemic progression. To test this idea, we first identified a recurrent BCR with nonmuscle myosin IIA autoreactivity among CD5 + B cells that progressed to CLL, promoted by expression of the Eμ-hTCL1 transgene. 21 By establishing a set of BCR transgenic/knock-in mouse models, we demonstrate that B-cell generation with this distinctive autoreactive BCR, having unique CDR3s, is restricted to B-1 development and poses a significant risk for progression to aggressive CLL/lymphoma. CLLs utilizing this BCR often show monoallelic loss of a region of mouse chromosome 14 that includes the miR15a/16-1 cluster, resembling human CLL.
MATERIALS AND METHODS Mice
Eμ-hTCL1 Tg mice were backcrossed onto the C.B17 background. To establish the V H Q52 VDJ knock-in line ON25, the V H Q52 IgH-μ transgenic mouse line OK44 and the V k 9-96 kappa (IgL) transgenic line OW26, heavy and light chains were cloned from the V H Q52/V k 9 hybridoma, 14-1H3. A detailed procedure to generate the zinc-finger nuclease (ZFN) knock-in mouse line ON25 is described in Supplementary Information. In brief, as shown in Figure 2c , RNA coding for two pairs of Fok I heterodimeric ZFNs cutting the mouse Ig heavy chain locus in J H 1 and just downstream of J H 4 was injected into oocytes, together with a 'donor' DNA segment containing the V H Q52/D/J H 4 segment, with 'arms' extending outside the ZFN target sites, facilitating homologous recombination into the J H region. To generate the V H Q52/D/J H 4-μ transgenic mouse line OK44, the rearrangement was cloned from hybridoma 14-1H3 DNA by long PCR using a primer upstream of the V H promoter region (identified from a database search) and a reverse primer downstream of the J H 4 segment. The promoter V H Q52/D/J H 4 segment was inserted into a Cμ vector previously used for generating heavy chain transgenic mice.
14 To generate the V k 9-96/J k 1-κ transgenic mouse line OW26, the kappa rearrangement was cloned from 14-1H3 DNA by long PCR using a primer sequence upstream of the Vκ promoter region and an antisense primer downstream of the Cκ segment. In all cases, PCR-amplified coding segments were verified as unmutated. lo CD5 +/lo 24E1id hi B cells were purified by sorting. Histologic diagnoses were made using formalin-fixed paraffin-embedded sections stained with hematoxylin and eosin using established criteria. 22 Flow cytometry analysis and anti-idiotype antibody
Multicolor flow cytometry analysis, sorting and monoclonal antibody reagents have been described previously, 15 and also listed in Supplementary Information. Rat anti-idiotype monoclonal IgG antibodies produced by hybridomas generated by immunizing rats with 14-1H3 IgM were made as described previously (Supplementary Information).
Immunoglobulin sequencing
Sequencing Igμ and Igκ variable regions of tumor B-cell BCRs by μ or κ PCR with consensus V primers was carried out using standard procedures in most cases. When sequences were not recovered, 5′ RACE cloning was performed using the SMARTer RACE cDNA amplification kit (Clontech, Mountain View, CA, USA). For single-cell sequencing, individual cells were deposited using a FACSAriaII (Becton Dickinson, San Jose, CA, USA), directly onto either AmpliGrid AG480F slides (Beckman Coulter, Brea, CA, USA) or onto 96-well plates prepared using a SuperScript III RT Kit (Life Technologies, Carlsbad, CA, USA). For details, see Supplementary Information.
Mouse V gene nomenclature
The V H gene family name is based on Johnston et al. 23 and V H gene classification is based on identity with genes in Vbase2 (www.Vbase2.org). AMyIIA V H Q52 has 100% identity with V222 from C57BL/6, closely related to the V H Ox-1 gene from BALB/c (V171) with some allelic differences. 24 V k gene nomenclature is based on Thiebe et al. 25 V k 9-96 is ce9.
Comparative genomic hybridization analysis
The Agilent DNA Microarray platform was employed for Array-CGH studies using the Agilent Mouse Genome CGH Microarray 244A chip with 235 000 mouse sequences. Procedures were performed in the Fox Chase Cancer Center Genomics Facility. Data were analyzed using BioDiscovery Nexus Copy Number software (El Segundo, CA, USA).
Tissue section and cell line immunofluorescence, and flow cytometry analysis
Rag1
− / − mice were used for producing ethanol-fixed frozen tissue sections, and microscope imaging was performed as described previously. 26, 27 1/100 diluted hybridoma IgM ascites ( 2-10 μg/ml after dilution) were incubated on tissue section slides for 90 min at 37°C, followed by AlexaFluor (AF) 488 anti-IgM (331.12), together with 4′,6-diamidino-2-phenylindole (Thermo Scientific, Rockford, IL, USA), with or without PE-anti-CD31 (eBioscience, San Diego, CA, USA; 30 min at room temperature). Quantitative reverse transcription PCR assay Gene expression was quantitated by real-time PCR, using TaqMan assays, an ABI 7500 real-time thermal cycler, and ABI software (all from Life Technologies).
Heavy chain-surrogate light-chain association analysis IgH-pMIG (MSCV-IRES-GFP) retroviral supernatants were generated as described in Supplementary Information. To examine surrogate light-chain (SLC) association, the Pro-B Abelson line N38 was transduced with IgH-pMIG retroviral supernatant. In GFP + cells, IgH-μ transduction was examined by intracellular IgM staining, and extent of SLC assembly was examined by surface SLC staining, using the conformationdependent anti-surrogate light-chain antibody SL156. 28 To test the capacity for pre-BCR-mediated proliferation, IgH-pMIG retroviral supernatant was added to Pro-B-cell cultures of Rag1 
RESULTS
Stereotyped V H Q52/V k 9 BCR in mouse CLL with deletion of a 14q chromosomal region containing miR15a/16-1 locus binds nonmuscle myosin IIA In mice, transgenic expression of the human T-cell leukemia 1 oncogene in B-lineage cells (Eμ-hTCL1) results in a high incidence of aggressive CD5 + CLL with a biased utilization of unmutated BCRs. 21, 29 Among these BCRs on a C.B17 mouse background, we found that a V H Q52 (V H Ox-1, V222)/V k 9 (V k 9-96) represented 9% of the total (14/155), and was a particularly restricted BCR with identical CDR3 and J segments ( Figure 1a ). Different from other TCL1 + (TC + ) CLLs, this TC + CLL often appeared as disseminated tumors in subcutaneous tissues (hypodermis), particularly in the cervical area including the salivary glands, resulting in a swollen neck (Figure 1b ). Comparative genomic hybridization (CGH) analysis revealed that 11/14 cases showed variable length hemizygous deletions in 14q that included the miR15a/16-1 locus, 30 syntenic to the 13q14 loss found in human CLL 31 ( Figure 1c ). To assess potential autoreactivity by this BCR, hybridomas were generated from CLL B cells. A V H Q52/V k 9 IgM was produced from hybridoma 14-1H3, and an IgM from hybridoma 54-2F3 as a control. Immunofluorescence screening of cryosections from mouse heart, lung, spleen and liver revealed strong binding by 14-1H3 IgM, specifically to blood clots in unperfused heart chambers ( Figure 1d ). Blood clots were CD31/PECAM-1 + with aggregated platelets. High reactivity to platelets raised the possibility of binding to non-muscle myosin IIA. 32 Confocal staining of the NIH-3T3 mouse fibroblast cell line showed that 14-1H3 staining co-localized with the phalloidin-stained F-actin filaments, the location of non-muscle myosin II, but not with the mitochondria (Figure 1e ).
Areas of actin filaments in the stromal cell line OP9 were also stained by 14-1H3 (Figure 1f ). Western blot analysis of OP9 cell extracts showed that 14-1H3 binds to a protein of~230 kDa, consistent with the size of non-muscle myosin II. This reactivity was abrogated by treatment with siRNA specific for the Myh9 gene that encodes myosin IIA, but not by siRNA for the Myh10 gene that encodes myosin IIB. This confirmed that the V H Q52/V k 9 IgM, 14-1H3, binds non-muscle myosin IIA (MyIIA; Figure 1g ). MyIIA is known to be present in most non-muscle eukaryotic cells, but also in muscle cells. 33 In addition to reactivity to platelets, fibroblasts and stromal cells, 14-1H3 also showed binding to MyIIA in a mouse B lymphoma, a neuroblast cell line and intestinal epithelium (Supplementary Figure 1) . Thus, this stereotyped BCR is autoreactive for MyIIA (AMyIIA) present in a variety of cell types.
The AMyIIA BCR B cells generated in the V H Q52/D/J knock-in mouse are B-1 derived The AMyIIA IgH V sequence was consistent with a fetal/neonatal origin, based on lack of N-addition at the V-D-J junctions, except for a p (palindrome)-nucleotide ( Figure 1a) . TdT (terminal deoxynucleotidyltransferase), an enzyme that mediates N-addition, is low/absent in B-lineage cells from mouse fetal liver. 34 Furthermore, this V H Q52 IgH failed to associate with SLC (Figure 2a ), leading to its inability to drive pre-BCR clonal expansion in BM (Figure 2b) . In adult B-2 development in BM, SLC assembles with IgH chain to generate a pre-BCR resulting in proliferation. However, for fetal B-1 development, strong IgH-SLC association is not required, 35 suggesting a preference for B-1 development. Therefore, to construct a mouse model ensuring physiologic expression of this AMyIIA BCR, we replaced the endogenous J H locus with this V H Q52/D/J using a ZFN-mediated approach (Figure 2c , details in Supplementary Information). This knock-in procedure allowed us to develop a strain, ON25, containing the VDJ J H insertion. B cells expressing this VDJ were identified by PBL staining with a V H Q52 idiotype-specific antibody ( Figure 2d ).
As in human cord blood, CD5 + B cells are present in early in life in normal mice. 13, 36, 37 One day after birth in ON25 mice (heterozygous knock-in), nearly all newly generated immature B cells in the liver expressed the V H Q52id + μ heavy chain, most with a κ light chain (Figure 2e, top) . AMyIIA BCR B cells already constituted 15-20% of the immature B cells stained by a V H Q52/ V k 9 idiotype-specific antibody, 24E1. Single-cell Igκ sequence analyses confirmed that V k 9 light chain was identical to that utilized in the AMyIIA BCR, specifically in cells showing higher + AMyIIA B cells also distributed to the intestine, including the colon, before B-2-derived B cells begin to accumulate (Figure 2g; Supplementary Figure 2) . In contrast, by 2 months after birth, the frequency of V H Q52id + cells among newly-formed B cells in BM was reduced to~40-50%, and production of AMyIIA immature B cells was significantly reduced (o 2%; Figure 2e, Figure 3a) . In the spleen, 24E1 hi cells (some CD23 lo AMyIIA B cells (Figure 4a , TC -), and gradually increased with age ( Figure 4c ). Thirty-four percent of the TC -mice developed a MBL when older than 15 months, and 13% (4/32) developed CLL (Table 1) , with or without splenomegaly, exemplified by the cases shown in Figure 4e . OK44 mice showed a similar outcome (Table 1) . Thus, even without the TCL1 transgene, we found progression to CLL, promoted by the novel AMyIIA BCR.
The incidence of 14q deletion (hemizygous) occurred at the MBL stage (data not shown), and in CLL, 75% (6/8) in TC + and 50% (4/8) in TC -, with subcutaneous infiltration, as originally described in Figure 1 . This 14q deletion of the miR15a/16-1 locus of varying length often included the Rb1 gene at 14qD3 (Figure 4d) as found in the human aggressive CLL subtype. 39 TC -ON25 sample #85 (Figure 4e, group 1) is a case of 14q deletion (Figure 4d , TC -9; Supplementary Figure 4) . Following an increase in AMyIIA B-cell frequency with a further reduction of B220 level in PBL, this ON25 mouse developed leukemia at 21 months. In addition to leukemic cells circulating through BM, such cells were also predominant in mesenteric lymph nodes, PerC (Supplementary Figure 5) , and infiltrated the salivary glands and subcutaneous tissues. Mice with (Figure 4e, group  2) . These TC -leukemia/lymphoma cases often (60%, 20/33) exhibited eventual loss of CD5, without mutation of the BCR, as has been found in some cases of human CLL.
Sharp downregulation of B220 is due to further altered glycosylation of CD45, without the loss of CD45 membrane expression, including CD45 isoform (Figure 5a, i) . In addition to this B220 low/-phenotype as seen in human CLL and mantle cell lymphoma, 40 retention of high-level CD38, increased CD43 and decreased CD62L, which were also common in mouse AMyIIA B CLL/lymphomas (Figure 5a , ii). ZAP70 expression was also observed in mice. At the CLL stage, the PerC had increased numbers of B cells in both TC -and TC + mice, due to leukemic cell deposition from vessels (Figure 5b, left) . Some of these leukemic lo+ in PBL (marked by triangle), followed by further downregulation of both B220 and CD5 (red triangle). 24E1 + AMyIIA cell and total B-cell percentages are shown.
AMyIIA B cells in the PerC (p) showed ZAP70 messenger RNA levels, often higher than in the spleen, as with the TC -#85 case (Figure 5b, marked red) . Thus, early generation of B cells with this AMyIIA BCR from B-1 development enhanced the risk for progression to aggressive CLL/lymphoma, and greatly increased the likelihood of loss of the miR15a/16-1 locus region, resembling human CLL. Addition of the Eμ-hTCL1 accelerated this CLL development process.
Further restriction of HCDR3 in B-1 B cells is required for progression to AMyIIA B-CLL It remained unclear how frequent this BCR is present in the normal mouse fetal/neonatal-derived B-cell repertoire, without V H Q52/D/J transgenesis. As shown in Figures 6a and b , CLLs with this stereotyped BCR developed following transfer of purified B1a cells from young (⩽2 months) animals, such as 1-month TC + mouse spleen, without BCR transgenesis. This confirmed that precursors for AMyIIA CLL are present among B1a cells in young mice. However, it was difficult to detect B1a with this BCR in young mice, indicating its low frequency. Thus, to pursue this issue, in particular to determine how restricted the heavy chain needs to be for CLL promotion, we developed a transgenic line expressing the AMyIIA V k 9 IgL, OW26, and evaluated IgH usage in 24E1 + cells by single-cell sequence analysis (Figure 6c (Figure 6d , TC + ), before the appearance of leukemia. These findings confirmed that rare AMyIIA stereotyped B cells were generated in neonatal/young mice in the B1a pool, that their frequency increased with age, becoming MBL, and that such cells were associated with an increased risk of progression to CLL. The TCL1 transgene promoted this leukemic process (Figure 6e) .
Importantly, analysis of OW26 V k 9 Tg mice revealed that none of the CD5 + 24E1 + B1a cells with V H Q52/D/J H 4 utilizing different CDR3s progressed to CLL, even in TC + mice without BCR transgenesis (where this BCR was originally identified as a 'stereotyped' V H /V L combination). Thus, not only was the variable region restricted, but there was a further key requirement for specific heavy and light chain CDR3s to generate AMyIIA CLLs from the B-1-derived B-cell pool. This indicates multiple steps of BCR signaling are involved in increasing the risk of leukemia/ lymphoma development ( Figure 7 ). B1a B-cell generation from fetal B-1 development is the first step involving selection by BCR signaling. Further BCR selection/restriction occurs during the self-renewal and proliferation of B-1 B cells, leading to CLL with a stereotyped unmutated BCR.
DISCUSSION
The origin of aggressive CLLs bearing unmutated BCRs has been long debated. 11 In humans, mature CD5 + B cells in healthy adults show enrichment of stereotyped V gene rearrangements, and the highest concordance in gene expression to CLL compared with other B subsets, lending support to the idea that CD5 + B cells may be precursors for CLL. 41 Here, in mice, we demonstrate that the life-long maintained early-generated B-1 B cell is one source of these CLLs. AMyIIA CLL incidence of B-1 B origin resembles human aggressive CLL, accompanied by occurrence of deletion of the 14q locus, as found in human CLLs (13q14 deletion). CD5 induction on B cells is a common outcome of mouse perinatal B-1 development that utilizes a BCR ligand-mediated signal for maturation, often by autoreactivity, thus resulting in a pool of cells with biased BCR usage and a B220 lo CD5
+ phenotype as B1a. Importantly, our analysis of AMyIIA B cells revealed that not all B1a cells progress stochastically to CLL; rather, a further BCR restriction emerged from our analysis. Clearly, CDR3 structure has an important role in this AMyIIA BCR. The arginine (R) residue in HCDR3, a charged amino acid, may be critical in providing crossreactivity 42 together with light chain. Autonomous signaling capacity 43 may also be involved in selecting B1a cells with distinctive BCRs. Thus, BCR selection is not a single-step process. Mouse AMyIIA IgM exhibits commensal bacteria crossreactivity (Supplementary Figure 6) . Microbiota provide crossreactive antigen(s) and also have an ability to trigger proliferation through TLR signal, suggesting that intestine may provide one such microenvironment. B-1 B cells generated in the neonatal liver initially distribute to intestinal mucosal tissues (Figure 2g ), in addition to the spleen and PerC, and have the ability to circulate through lymphatic and blood vessels in the adult, including the intestine. 15, 44, 45 Subcutaneous infiltration at leukemic stage is a unique feature found in this mouse AMyIIA CLL. Non-muscle myosin IIA is a central integrator to regulate cell migration and adhesion. 33 As our mouse AMyIIA models on a C.B17 mouse background showed high natural AMyIIA autoantibody production in serum (data not shown), continuous production of antibody and/or internal IgM interaction with the cytoskeleton may have contributed to this unique outcome. One possibility is the platelet aggregation by AMyIIA antibody, which may be responsible for blockage of leukemic B-cell circulation from lymphatic vessels to the subclavian vein, 46 leading to infiltration of the neck region promoted by deregulation of the miR15a/16-1 cluster. Targeted deletion in mouse of regions encompassing the miR15a/16-1 cluster promotes MBL/CLL, including cases with hemizygous deletion, 30, 47 and around 80% of human CLL with 13q14 deletion is monoallelic. Thus, hemizygous deletion of 14q in mouse AMyIIA CLL appears to be sufficient to promote lymphoproliferation and infiltration.
Whether the AMyIIA CLL origin that we observed with mice also occurs in humans is an important issue for further investigation. Although there are no highly similar mouse and human V H gene protein sequences, the human germline V H most similar to mouse V H Q52 AMyIIA BCR is V H 4-59 with 64% identity, and 83% similarity in framework segment FR1. Interestingly, V H 4-59 (V71-4) is expressed by B cells at the fetal/neonatal stage in humans, with increased usage in aged individuals, 48, 49 and is found in human CLL.
2 A well-known stereotyped AMyIIA CLL BCR in human is the V H 1-69/D3-16/J3 IgH paired with IgKV3-20 IgL 7,8 with polyreactivity. 50, 51 This IgH rearrangement utilizes nearly identical CDR3s of greater length, also implying an important role for CDR3. 52 V H 1-69-expressing B-lineage cells are present in human fetal liver, 53 and V H 1-69 is one of the predominant V H gene families found in unmutated CLLs 8, 54 with crossreactivity to virus and also to intestinal commensal bacteria. 55 V H 1-69-expressing B cells can be detected in healthy elderly individuals, 56 but not at increased frequency, and this particular V H 1-69/D/J3 IgH rearrangement is not readily detectable in aged humans. 57 Similarly, in mice, although V H Q52 IgH is preferentially utilized early in life, the CLL-associated stereotype AMyIIA BCR is infrequent both in neonatal and aged mice. However, mouse BCR model analysis made it clear that CLLs with this BCR arise from B cells generated by early fetal/neonatal B-1 development, promoted by TCL1 transgenesis. Higher TCL1 expression is also correlated with aggressive B CLL in humans. 58 Thus, human AMyIIA CLLs may also involve selection of particular CDR3s from an early-generated B-cell pool, promoted both by genetic and exogenous influences. Whether mouse-like fetal B-1 development occurs in humans remains an unanswered question. However, the differential expression patterns of Lin28b that distinguishes fetal and adult hematopoietic cells in mice has also been found in humans, 17 and CD5 + B-cell generation, including at the immature stage, is the predominant outcome of development in the human fetus and in cord blood. 36, 37, 59 As the level of TdT is lower in human fetal development than adult, but is upregulated much earlier than in mice, 60 N-addition in human V H 1-69/D3-16/J3 with a longer CDR3 does not exclude fetal/neonatal generation. Our mouse AMyIIA BCR CLL data raises the interesting possibility that distinctive fetal/ neonatal B-1 development in humans may also generate a pool of self-reactive B cells that serve as precursors for unmutated BCR CLLs, where specific BCRs selected by this development, on certain genetic backgrounds, pose a high risk for leukemic progression. 
